Activation	O
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
enhancer	I-DNA
is	O
not	O
dependent	O
on	O
NFAT-1	B-protein
.	O

The	O
function	O
of	O
a	O
putative	B-DNA
NFAT-1	I-DNA
site	I-DNA
in	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
enhancer	I-DNA
has	O
been	O
analyzed	O
.	O

Activation	O
by	O
the	O
T-cell	B-protein
antigen	I-protein
receptor	I-protein
is	O
minimal	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
and	O
is	O
mediated	O
by	O
the	O
kappa	B-DNA
B	I-DNA
sites	I-DNA
.	O

The	O
putative	B-DNA
NFAT-1	I-DNA
region	I-DNA
is	O
not	O
required	O
for	O
the	O
response	O
to	O
anti-CD3	B-protein
or	O
to	O
mitogens	B-protein
in	O
T-cell	B-cell_line
,	O
B-cell	B-cell_line
,	O
or	O
monocyte/macrophage	B-cell_line
leukemia	I-cell_line
lines	I-cell_line
,	O
nor	O
is	O
it	O
a	O
cis-acting	B-DNA
negative	I-DNA
regulatory	I-DNA
element	I-DNA
.	O

JOURNAL	NULL
OF	NULL
VIROLOGY	NULL
,	NULL
June	NULL
1992	NULL
,	NULL
p.	NULL
3961-3965	NULL
0022-538	NULL
X/92/063961-05	NULL
$	NULL
02.00/0	NULL
Copyright	NULL
©	NULL
1992	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

66	NULL
,	NULL
No	NULL
.	NULL

6	NULL
Activation	NULL
of	NULL
the	NULL
Human	NULL
Immunodeficiency	NULL
Virus	NULL
Type	NULL
1	NULL
Enhancer	NULL
Is	NULL
Not	NULL
Dependent	NULL
on	NULL
NFAT-1	NULL
DAVID	NULL
M.	NULL
MARKOVITZ	NULL
,	NULL
'	NULL
MARK	NULL
C.	NULL
HANNIBAL	NULL
,	NULL
*2	NULL
>	NULL
MICHAEL	NULL
J.	NULL
SMITH	NULL
,	NULL
!	NULL

RONALD	NULL
COSSMAN	NULL
,	NULL
*	NULL
anp	NULL
GARY	NULL
J.	NULL
NABEL2**	NULL
Howard	NULL
Hughes	NULL
Medical	NULL
Institute®	NULL
and	NULL
Departments	NULL
of	NULL
Internal	NULL
Medicine®	NULL
and	NULL
Biological	NULL
Chemistry	NULL
,	NULL
``	NULL
University	NULL
of	NULL
Michigan	NULL
Medical	NULL
Center	NULL
,	NULL
Ann	NULL
Arbor	NULL
,	NULL
Michigan	NULL
48109-0650	NULL
Received	NULL
28	NULL
May	NULL
1991/Accepted	NULL
25	NULL
February	NULL
1992	NULL
The	NULL
function	NULL
of	NULL
a	NULL
putative	NULL
NFAT-1	NULL
site	NULL
in	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
enhancer	NULL
has	NULL
been	NULL
analyzed	NULL
.	NULL

Activation	NULL
by	NULL
the	NULL
T-cell	NULL
antigen	NULL
receptor	NULL
is	NULL
minimal	NULL
in	NULL
Jurkat	NULL
cells	NULL
and	NULL
is	NULL
mediated	NULL
by	NULL
the	NULL
iB	NULL
sites	NULL
.	NULL

The	NULL
putative	NULL
NFAT-1	NULL
region	NULL
is	NULL
not	NULL
required	NULL
for	NULL
the	NULL
response	NULL
to	NULL
anti-CD3	NULL
or	NULL
to	NULL
mitogens	NULL
in	NULL
T-cell	NULL
,	NULL
B-cell	NULL
,	NULL
or	NULL
monocyte/macrophage	NULL
leukemia	NULL
lines	NULL
,	NULL
nor	NULL
is	NULL
it	NULL
a	NULL
cis-acting	NULL
negative	NULL
regulatory	NULL
element	NULL
.	NULL

Transcription	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
in	NULL
T	NULL
lymphocytes	NULL
is	NULL
regulated	NULL
by	NULL
specific	NULL
cellular	NULL
activation	NULL
pathways	NULL
stimulated	NULL
by	NULL
triggering	NULL
of	NULL
distinct	NULL
cell	NULL
surface	NULL
receptors	NULL
.	NULL

kB	NULL
regulatory	NULL
elements	NULL
of	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
are	NULL
required	NULL
for	NULL
transcriptional	NULL
activation	NULL
after	NULL
mitogen	NULL
or	NULL
cytokine	NULL
stimulation	NULL
(	NULL
21	NULL
,	NULL
22	NULL
)	NULL
.	NULL

At	NULL
least	NULL
two	NULL
cis-acting	NULL
regulatory	NULL
elements	NULL
respond	NULL
to	NULL
stimulation	NULL
of	NULL
the	NULL
T-cell	NULL
antigen	NULL
receptor	NULL
,	NULL
the	NULL
site	NULL
which	NULL
binds	NULL
the	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
NFAT-1	NULL
)	NULL
in	NULL
the	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
gene	NULL
(	NULL
3	NULL
,	NULL
27	NULL
)	NULL
,	NULL
and	NULL
the	NULL
CD3-responsive	NULL
site	NULL
(	NULL
20	NULL
)	NULL
of	NULL
HIV-2	NULL
.	NULL

The	NULL
NFAT-1	NULL
site	NULL
in	NULL
the	NULL
IL-2	NULL
enhancer	NULL
resembles	NULL
a	NULL
binding	NULL
site	NULL
for	NULL
the	NULL
ets	NULL
proto-oncogene	NULL
and	NULL
is	NULL
recognized	NULL
by	NULL
ets	NULL
family	NULL
members	NULL
(	NULL
29	NULL
,	NULL
33	NULL
)	NULL
.	NULL

The	NULL
function	NULL
of	NULL
these	NULL
cis-acting	NULL
enhancer	NULL
elements	NULL
in	NULL
their	NULL
respective	NULL
enhancers	NULL
has	NULL
been	NULL
demonstrated	NULL
(	NULL
3	NULL
,	NULL
20	NULL
,	NULL
27	NULL
)	NULL
,	NULL
but	NULL
their	NULL
role	NULL
in	NULL
HIV-1	NULL
gene	NULL
regulation	NULL
,	NULL
if	NULL
any	NULL
,	NULL
has	NULL
not	NULL
been	NULL
precisely	NULL
defined	NULL
.	NULL

The	NULL
putative	NULL
NFAT-1	NULL
binding	NULL
site	NULL
in	NULL
HIV-1	NULL
was	NULL
originally	NULL
identified	NULL
when	NULL
a	NULL
factor	NULL
in	NULL
stimulated	NULL
Jurkat	NULL
T-cell	NULL
extracts	NULL
,	NULL
and	NULL
later	NULL
partially	NULL
purified	NULL
NFAT-1	NULL
,	NULL
was	NULL
shown	NULL
to	NULL
bind	NULL
the	NULL
enhancer	NULL
between	NULL
positions	NULL
-216	NULL
and	NULL
-254	NULL
by	NULL
DNase	NULL
footprinting	NULL
(	NULL
1	NULL
,	NULL
27	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
,	NULL
NFp	NULL
and	NULL
NF	NULL
'	NULL
p	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
region	NULL
showing	NULL
DNase	NULL
protection	NULL
is	NULL
adjacent	NULL
to	NULL
but	NULL
does	NULL
not	NULL
overlap	NULL
the	NULL
purine-rich	NULL
region	NULL
of	NULL
sequence	NULL
homology	NULL
that	NULL
is	NULL
shared	NULL
by	NULL
HIV-1	NULL
and	NULL
the	NULL
NFAT-1	NULL
binding	NULL
site	NULL
of	NULL
the	NULL
IL-2	NULL
enhancer	NULL
(	NULL
PuB	NULL
,	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
(	NULL
6	NULL
,	NULL
27	NULL
,	NULL
33	NULL
)	NULL
.	NULL

Despite	NULL
this	NULL
discrepancy	NULL
and	NULL
the	NULL
lack	NULL
of	NULL
functional	NULL
data	NULL
on	NULL
specific	NULL
mutations	NULL
of	NULL
this	NULL
site	NULL
,	NULL
NFAT-1	NULL
has	NULL
been	NULL
assumed	NULL
to	NULL
play	NULL
a	NULL
role	NULL
in	NULL
the	NULL
response	NULL
of	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
to	NULL
T-cell	NULL
stimulation	NULL
(	NULL
10	NULL
,	NULL
27	NULL
,	NULL
32	NULL
)	NULL
.	NULL

Our	NULL
previous	NULL
data	NULL
(	NULL
20	NULL
,	NULL
21	NULL
)	NULL
demonstrated	NULL
that	NULL
mutation	NULL
of	NULL
the	NULL
«	NULL
B	NULL
sites	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
of	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
abolishes	NULL
enhancer	NULL
activation	NULL
in	NULL
stimulated	NULL
T	NULL
cells	NULL
,	NULL
but	NULL
the	NULL
data	NULL
did	NULL
not	NULL
exclude	NULL
the	NULL
possibility	NULL
that	NULL
HIV-1	NULL
activation	NULL
was	NULL
also	NULL
dependent	NULL
on	NULL
an	NULL
intact	NULL
NFAT-like	NULL
element	NULL
.	NULL

Therefore	NULL
,	NULL
to	NULL
elucidate	NULL
the	NULL
function	NULL
of	NULL
the	NULL
putative	NULL
NFAT-1	NULL
site	NULL
of	NULL
HIV-1	NULL
and	NULL
to	NULL
examine	NULL
the	NULL
role	NULL
of	NULL
the	NULL
T-cell	NULL
receptor	NULL
signal	NULL
trans-duction	NULL
pathway	NULL
in	NULL
HIV-1	NULL
stimulation	NULL
,	NULL
we	NULL
have	NULL
investigated	NULL
the	NULL
role	NULL
of	NULL
this	NULL
element	NULL
in	NULL
regulation	NULL
of	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
after	NULL
T-cell	NULL
activation	NULL
.	NULL

Stimulation	NULL
of	NULL
T	NULL
cells	NULL
by	NULL
phorbol	NULL
esters	NULL
or	NULL
certain	NULL
cyto-kines	NULL
results	NULL
in	NULL
increased	NULL
expression	NULL
of	NULL
HIV-1	NULL
(	NULL
21	NULL
,	NULL
22	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
HIV-2	NULL
enhancer	NULL
,	NULL
treatment	NULL
of	NULL
Jurkat	NULL
cells	NULL
with	NULL
antibodies	NULL
to	NULL
the	NULL
T-cell	NULL
receptor	NULL
does	NULL
not	NULL
stimulate	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
(	NULL
20	NULL
)	NULL
,	NULL
but	NULL
activation	NULL
with	NULL
antibodies	NULL
to	NULL
the	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

3961	NULL
T-cell	NULL
receptor	NULL
which	NULL
have	NULL
been	NULL
cross-linked	NULL
induces	NULL
a	NULL
small	NULL
but	NULL
measurable	NULL
stimulation	NULL
(	NULL
13	NULL
,	NULL
31	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
the	NULL
region	NULL
with	NULL
NFAT-1	NULL
homology	NULL
(	NULL
PuB	NULL
)	NULL
or	NULL
the	NULL
region	NULL
of	NULL
nuclear	NULL
factor	NULL
protection	NULL
(	NULL
NFp	NULL
)	NULL
mediates	NULL
changes	NULL
in	NULL
gene	NULL
expression	NULL
following	NULL
T-cell	NULL
activation	NULL
,	NULL
we	NULL
performed	NULL
a	NULL
mutational	NULL
analysis	NULL
of	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
.	NULL

Site-specific	NULL
mutations	NULL
(	NULL
21	NULL
)	NULL
were	NULL
introduced	NULL
into	NULL
plasmids	NULL
containing	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
linked	NULL
to	NULL
the	NULL
chloramphenicol	NULL
acetyltrans-ferase	NULL
(	NULL
CAT	NULL
)	NULL
gene	NULL
(	NULL
HIV-1-CAT	NULL
;	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
(	NULL
25	NULL
)	NULL
,	NULL
and	NULL
these	NULL
plasmids	NULL
(	NULL
5	NULL
ug	NULL
)	NULL
were	NULL
transfected	NULL
into	NULL
10	NULL
``	NULL
Jurkat	NULL
T	NULL
leukemia	NULL
cells	NULL
by	NULL
using	NULL
DEAE-dextran	NULL
(	NULL
24	NULL
)	NULL
.	NULL

At	NULL
20	NULL
h	NULL
following	NULL
trans-fection	NULL
,	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
(	NULL
PMA	NULL
;	NULL
16	NULL
nM	NULL
)	NULL
and	NULL
phytohemagglutinin	NULL
(	NULL
PHA	NULL
;	NULL
2	NULL
pg/ml	NULL
!	NULL
)	NULL

for	NULL
an	NULL
additional	NULL
20	NULL
h.	NULL
This	NULL
treatment	NULL
increased	NULL
CAT	NULL
activity	NULL
11-fold	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

Mutation	NULL
of	NULL
either	NULL
the	NULL
PuB	NULL
or	NULL
protected	NULL
sites	NULL
did	NULL
not	NULL
significantly	NULL
alter	NULL
the	NULL
response	NULL
to	NULL
PMA	NULL
and	NULL
PHA	NULL
,	NULL
although	NULL
slightly	NULL
lower	NULL
basal	NULL
activity	NULL
was	NULL
observed	NULL
in	NULL
the	NULL
NF	NULL
,	NULL
mutant	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
a	NULL
second	NULL
site	NULL
in	NULL
the	NULL
3	NULL
'	NULL
portion	NULL
of	NULL
the	NULL
NFAT-1	NULL
footprint	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
bind	NULL
partially	NULL
purified	NULL
NFAT-1	NULL
(	NULL
4	NULL
)	NULL
.	NULL

A	NULL
mutation	NULL
was	NULL
introduced	NULL
into	NULL
this	NULL
site	NULL
(	NULL
NF	NULL
'	NULL
p	NULL
,	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
,	NULL
and	NULL
in	NULL
separate	NULL
experiments	NULL
,	NULL
the	NULL
response	NULL
of	NULL
the	NULL
mutant	NULL
plasmid	NULL
to	NULL
PMA	NULL
and	NULL
PHA	NULL
was	NULL
compared	NULL
with	NULL
that	NULL
of	NULL
the	NULL
wild	NULL
type	NULL
in	NULL
Jurkat	NULL
cells	NULL
.	NULL

No	NULL
significant	NULL
effect	NULL
of	NULL
this	NULL
mutation	NULL
was	NULL
seen	NULL
on	NULL
either	NULL
basal	NULL
or	NULL
induced	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
mutation	NULL
of	NULL
the	NULL
two	NULL
«	NULL
B	NULL
sites	NULL
eliminated	NULL
stimulation	NULL
by	NULL
PMA	NULL
and	NULL
PHA	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
,	NULL
consistent	NULL
with	NULL
previous	NULL
studies	NULL
(	NULL
21	NULL
)	NULL
.	NULL

When	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
were	NULL
stimulated	NULL
by	NULL
cross-linking	NULL
of	NULL
antibodies	NULL
to	NULL
the	NULL
T-cell	NULL
receptor	NULL
,	NULL
minimal	NULL
activation	NULL
(	NULL
ca	NULL
.	NULL

threefold	NULL
)	NULL
was	NULL
seen	NULL
,	NULL
and	NULL
this	NULL
limited	NULL
effect	NULL
was	NULL
abolished	NULL
when	NULL
the	NULL
KB	NULL
sites	NULL
were	NULL
mutated	NULL
(	NULL
Fig	NULL
.	NULL

1D	NULL
)	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
PuB	NULL
or	NULL
NF	NULL
»	NULL
element	NULL
did	NULL
not	NULL
affect	NULL
CAT	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

1D	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
similar	NULL
stimulation	NULL
of	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
HIV-2	NULL
enhancer	NULL
resulted	NULL
in	NULL
~30-fold	NULL
induction	NULL
,	NULL
highlighting	NULL
the	NULL
differential	NULL
responsiveness	NULL
of	NULL
these	NULL
two	NULL
viral	NULL
enhancers	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
observed	NULL
for	NULL
HIV-1	NULL
and	NULL
these	NULL
mutants	NULL
following	NULL
activation	NULL
of	NULL
Jurkat	NULL
cells	NULL
by	NULL
PMA	NULL
or	NULL
PHA	NULL
alone	NULL
or	NULL
in	NULL
the	NULL
mouse	NULL
T-cell	NULL
line	NULL
ELA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
(	NULL
20	NULL
,	NULL
21	NULL
)	NULL
.	NULL

In	NULL
the	NULL
experiments	NULL
with	NULL
ELA	NULL
cells	NULL
,	NULL
25-	NULL
to	NULL
100-fold	NULL
induction	NULL
of	NULL
the	NULL
IL-2	NULL
enhancer	NULL
was	NULL
seen	NULL
,	NULL
and	NULL
site-specific	NULL
mutation	NULL
of	NULL
the	NULL
NFAT-1	NULL
site	NULL
in	NULL
the	NULL
IL-2	NULL
enhancer	NULL
reduced	NULL
stimulation	NULL
10-	NULL
to	NULL
25-fold	NULL
(	NULL
12	NULL
)	NULL
.	NULL

These	NULL
results	NULL
show	NULL
that	NULL
functionally	NULL
active	NULL
NFAT-1	NULL
was	NULL
made	NULL
in	NULL
these	NULL
cells	NULL
but	NULL
did	NULL
not	NULL
stimulate	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
.	NULL

Cells	NULL
of	NULL
the	NULL
monocyte/macrophage	NULL
lineage	NULL
are	NULL
also	NULL
an	NULL
important	NULL
reservoir	NULL
for	NULL
HIV	NULL
infection	NULL
in	NULL
vivo	NULL
(	NULL
5	NULL
,	NULL
7	NULL
,	NULL
8	NULL
,	NULL
16	NULL
)	NULL
.	NULL

In	NULL
3962	NULL
NOTES	NULL
J.	NULL
Viror	NULL
.	NULL

translation	NULL
A	NULL
xB	NULL
Sp1	NULL
TATA	NULL
box	NULL
cap	NULL
site	NULL
-	NULL
initiation	NULL
A	NULL
]	NULL
/	NULL
_	NULL
-453	NULL
-275	NULL
-215	NULL
-~104	NULL
-90	NULL
-25	NULL
1	NULL
Bo	NULL
IL-2	NULL
Homology	NULL
NFAT	NULL
DNase	NULL
footprint	NULL
T	NULL
a	NULL
;	NULL
CCAATAAAGGAGAGAACACCAGCTTGTTACACCCTGTGAGCCTGCATGGGATGGATGACCC	NULL
AAGGAGAGAA	NULL
ecTTaTTAcA	NULL
'A1eceaTeGA	NULL
Mutant	NULL
:	NULL
CCAAGCTTCG	NULL
CTCGAGGCAC	NULL
GCTAAGCTTG	NULL
PuB	NULL
NF	NULL
,	NULL
NF	NULL
``	NULL
A	NULL
A	NULL
p	NULL
A	NULL
p	NULL
B	NULL
.	NULL

-	NULL
TRANSFECTED	NULL
C.	NULL
-	NULL
TRANSFECTED	NULL
D.	NULL
_	NULL
TRANSFECTED	NULL
PLASMID	NULL
:	NULL
-	NULL
HIV-1	NULL
A	NULL
PuB	NULL
_	NULL
A	NULL
NFP	NULL
ArB	NULL
PLASMID	NULL
:	NULL
_	NULL
HIV-1	NULL
A	NULL
NF	NULL
}	NULL
;	NULL
PLASMID	NULL
:	NULL
_	NULL
HIV-1	NULL
A	NULL
PuB	NULL
_	NULL
A	NULL
NFP	NULL
AxB	NULL
-CAT	NULL
OOT	NULL
O3	NULL
25	NULL
50	NULL
5	NULL
CONVERSION	NULL
CONVERSION	NULL
CONVERSION	NULL
(	NULL
%	NULL
)	NULL
(	NULL
%	NULL
)	NULL
(	NULL
%	NULL
)	NULL
STIMULANT	NULL
STIMULANT	NULL
STIMULANT	NULL
PMA	NULL
+	NULL
PHA	NULL
:	NULL
-	NULL
+	NULL
~o4	NULL
o-	NULL
+	NULL
PMA+PHA	NULL
:	NULL
-	NULL
+	NULL
-	NULL
+	NULL
anti-CD3	NULL
:	NULL
-	NULL
+	NULL
-	NULL
+	NULL
-	NULL
+	NULL
-	NULL
+	NULL
FOLD	NULL
INDUCTION	NULL
:	NULL
11.0	NULL
18.6	NULL
12.8	NULL
<	NULL
1	NULL
FOLD	NULL
INDUCTION	NULL
:	NULL
29.7	NULL
22.9	NULL
FOLD	NULL
INDUCTION	NULL
:	NULL
2.5	NULL
3.2	NULL
4.0	NULL
1.2	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Site-specific	NULL
mutations	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
and	NULL
their	NULL
effect	NULL
on	NULL
expression	NULL
in	NULL
stimulated	NULL
Jurkat	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Schematic	NULL
representation	NULL
of	NULL
the	NULL
relevant	NULL
enhancer	NULL
region	NULL
of	NULL
HIV-1	NULL
.	NULL

Altered	NULL
bases	NULL
within	NULL
the	NULL
mutant	NULL
plasmids	NULL
used	NULL
in	NULL
this	NULL
study	NULL
are	NULL
shown	NULL
below	NULL
the	NULL
wild-type	NULL
sequence	NULL
.	NULL

The	NULL
region	NULL
of	NULL
homology	NULL
to	NULL
the	NULL
IL-2	NULL
enhancer	NULL
(	NULL
6	NULL
)	NULL
,	NULL
PuB	NULL
,	NULL
and	NULL
the	NULL
sites	NULL
of	NULL
DNase	NULL
protection	NULL
(	NULL
NFp	NULL
and	NULL
NF	NULL
'	NULL
p	NULL
[	NULL
27	NULL
]	NULL
)	NULL
are	NULL
indicated	NULL
.	NULL

(	NULL
B	NULL
)	NULL
The	NULL
roles	NULL
of	NULL
PuB	NULL
,	NULL
NFp	NULL
,	NULL
and	NULL
«	NULL
B	NULL
sites	NULL
in	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
were	NULL
determined	NULL
by	NULL
transfection	NULL
of	NULL
the	NULL
indicated	NULL
wild-type	NULL
and	NULL
mutant	NULL
plasmids	NULL
into	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

Cell	NULL
extracts	NULL
were	NULL
prepared	NULL
,	NULL
and	NULL
CAT	NULL
activity	NULL
was	NULL
determined	NULL
by	NULL
standard	NULL
methods	NULL
(	NULL
9	NULL
)	NULL
.	NULL

Transfection	NULL
efficiencies	NULL
were	NULL
normalized	NULL
to	NULL
protein	NULL
concentration	NULL
.	NULL

Values	NULL
for	NULL
percent	NULL
conversion	NULL
of	NULL
chloramphenicol	NULL
to	NULL
acetylated	NULL
forms	NULL
shown	NULL
are	NULL
the	NULL
average	NULL
of	NULL
two	NULL
independent	NULL
transfections	NULL
and	NULL
representative	NULL
of	NULL
a	NULL
total	NULL
of	NULL
three	NULL
to	NULL
six	NULL
independent	NULL
transfections	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Effect	NULL
of	NULL
site-specific	NULL
mutation	NULL
of	NULL
the	NULL
NF	NULL
'	NULL
p	NULL
site	NULL
on	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
.	NULL

Values	NULL
shown	NULL
are	NULL
the	NULL
average	NULL
of	NULL
two	NULL
independent	NULL
transfections	NULL
.	NULL

(	NULL
D	NULL
)	NULL
The	NULL
role	NULL
of	NULL
cis-acting	NULL
regulatory	NULL
sequences	NULL
in	NULL
the	NULL
stimulation	NULL
of	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
by	NULL
antibodies	NULL
to	NULL
the	NULL
T-cell	NULL
receptor	NULL
was	NULL
determined	NULL
.	NULL

The	NULL
anti-CD3	NULL
(	NULL
OKT3	NULL
)	NULL
monoclonal	NULL
antibody	NULL
(	NULL
1:1,000	NULL
dilution	NULL
of	NULL
mouse	NULL
ascites	NULL
fluid	NULL
)	NULL
was	NULL
immobilized	NULL
on	NULL
the	NULL
tissue	NULL
culture	NULL
plate	NULL
with	NULL
a	NULL
10-ug/ml	NULL
dilution	NULL
of	NULL
goat	NULL
anti-mouse	NULL
immunoglobulin	NULL
G	NULL
(	NULL
Kirkegaard	NULL
&	NULL
Perry	NULL
)	NULL
.	NULL

Values	NULL
shown	NULL
are	NULL
the	NULL
average	NULL
of	NULL
two	NULL
independent	NULL
transfections	NULL
and	NULL
are	NULL
representative	NULL
of	NULL
four	NULL
independent	NULL
transfections	NULL
.	NULL

mature	NULL
cells	NULL
,	NULL
NF-kB	NULL
binding	NULL
activity	NULL
is	NULL
readily	NULL
detected	NULL
and	NULL
plasmids	NULL
again	NULL
showed	NULL
expression	NULL
similar	NULL
to	NULL
the	NULL
wild	NULL
type	NULL
is	NULL
not	NULL
further	NULL
induced	NULL
by	NULL
treatment	NULL
with	NULL
PMA	NULL
(	NULL
11	NULL
)	NULL
.	NULL

In	NULL
these	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

These	NULL
experiments	NULL
suggest	NULL
that	NULL
the	NULL
PuB	NULL
and	NULL
NF	NULL
,	NULL
cells	NULL
,	NULL
another	NULL
transcription	NULL
factor	NULL
,	NULL
PU.1	NULL
,	NULL
has	NULL
been	NULL
shown	NULL
elements	NULL
are	NULL
not	NULL
required	NULL
for	NULL
induction	NULL
of	NULL
the	NULL
HIV-1	NULL
en-recently	NULL
to	NULL
bind	NULL
purine-rich	NULL
sequences	NULL
similar	NULL
to	NULL
the	NULL
purine-	NULL
hancer	NULL
in	NULL
T	NULL
,	NULL
B	NULL
,	NULL
or	NULL
monocytic	NULL
leukemia	NULL
cells	NULL
and	NULL
suggests	NULL
rich	NULL
binding	NULL
site	NULL
in	NULL
the	NULL
NFAT-1	NULL
element	NULL
of	NULL
the	NULL
IL-2	NULL
enhancer	NULL
that	NULL
,	NULL
while	NULL
a	NULL
protein	NULL
may	NULL
bind	NULL
to	NULL
the	NULL
NFp	NULL
element	NULL
in	NULL
vitro	NULL
,	NULL
(	NULL
15	NULL
,	NULL
23	NULL
)	NULL
,	NULL
which	NULL
somewhat	NULL
resembles	NULL
the	NULL
HIV-1	NULL
PuB	NULL
site	NULL
.	NULL

To	NULL
this	NULL
interaction	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
be	NULL
functionally	NULL
significant	NULL
determine	NULL
whether	NULL
the	NULL
PuB	NULL
and	NULL
NF	NULL
»	NULL
sites	NULL
functioned	NULL
differ-	NULL
in	NULL
several	NULL
cell	NULL
types	NULL
.	NULL

ently	NULL
in	NULL
macrophage	NULL
leukemia	NULL
lines	NULL
,	NULL
a	NULL
mature	NULL
monocyte	NULL
Transactivation	NULL
by	NULL
viral	NULL
genes	NULL
also	NULL
leads	NULL
to	NULL
HIV	NULL
enhancer	NULL
leukemia	NULL
line	NULL
,	NULL
THP-1	NULL
,	NULL
was	NULL
transfected	NULL
with	NULL
the	NULL
HIV-1-CAT	NULL
activation	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
the	NULL
fax	NULL
,	NULL
gene	NULL
of	NULL
human	NULL
T-cell	NULL
or	NULL
mutant	NULL
plasmids	NULL
.	NULL

Consistent	NULL
with	NULL
its	NULL
high	NULL
constitutive	NULL
lymphotropic	NULL
virus	NULL
type	NULL
I	NULL
(	NULL
HTLV-I	NULL
)	NULL
,	NULL
deletion	NULL
of	NULL
upstream	NULL
levels	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
11	NULL
)	NULL
,	NULL
THP-1	NULL
cells	NULL
transfected	NULL
with	NULL
HIV-1	NULL
enhancer	NULL
sequences	NULL
has	NULL
been	NULL
suggested	NULL
to	NULL
increase	NULL
the	NULL
CAT	NULL
showed	NULL
no	NULL
increase	NULL
in	NULL
CAT	NULL
activity	NULL
after	NULL
PMA	NULL
treat-	NULL
minimal	NULL
stimulation	NULL
of	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
(	NULL
28	NULL
)	NULL
,	NULL
possibly	NULL
ment	NULL
,	NULL
and	NULL
the	NULL
kB	NULL
mutant	NULL
displayed	NULL
markedly	NULL
lower	NULL
basal	NULL
due	NULL
to	NULL
a	NULL
negative	NULL
regulatory	NULL
element	NULL
between	NULL
-278	NULL
and	NULL
expression	NULL
(	NULL
11	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
.	NULL

Both	NULL
the	NULL
PuB	NULL
and	NULL
NFp	NULL
mutants	NULL
-117	NULL
which	NULL
impairs	NULL
the	NULL
fax	NULL
,	NULL
response	NULL
.	NULL

To	NULL
investigate	NULL
showed	NULL
no	NULL
difference	NULL
in	NULL
CAT	NULL
activity	NULL
after	NULL
mitogen	NULL
treat-	NULL
whether	NULL
the	NULL
PuB	NULL
or	NULL
NFp	NULL
site	NULL
acts	NULL
as	NULL
a	NULL
negative	NULL
regulatory	NULL
ment	NULL
,	NULL
and	NULL
the	NULL
mutant	NULL
plasmids	NULL
showed	NULL
activity	NULL
similar	NULL
to	NULL
element	NULL
for	NULL
tax	NULL
,	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
a	NULL
fax	NULL
,	NULL
that	NULL
of	NULL
the	NULL
wild-type	NULL
enhancer	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
.	NULL

To	NULL
examine	NULL
the	NULL
role	NULL
expression	NULL
plasmid	NULL
and	NULL
HIV-1-CAT	NULL
or	NULL
mutant	NULL
plasmids	NULL
.	NULL

of	NULL
these	NULL
elements	NULL
in	NULL
B	NULL
cells	NULL
,	NULL
which	NULL
also	NULL
express	NULL
PU.1	NULL
,	NULL
these	NULL
Cotransfection	NULL
with	NULL
tax	NULL
,	NULL
resulted	NULL
in	NULL
a	NULL
ca	NULL
.	NULL

threefold	NULL
stimula-plasmids	NULL
were	NULL
introduced	NULL
into	NULL
an	NULL
Epstein-Barr	NULL
virus-trans-	NULL
tion	NULL
of	NULL
HIV-1-CAT	NULL
,	NULL
which	NULL
did	NULL
not	NULL
differ	NULL
significantly	NULL
from	NULL
formed	NULL
B-cell	NULL
leukemia	NULL
line	NULL
,	NULL
clone	NULL
13	NULL
.	NULL

PuB	NULL
and	NULL
NFp	NULL
mutant	NULL
the	NULL
result	NULL
after	NULL
cotransfection	NULL
of	NULL
tax	NULL
,	NULL
with	NULL
the	NULL
PuB	NULL
or	NULL
NF	NULL
,	NULL
Vor	NULL
.	NULL

66	NULL
,	NULL
1992	NULL
A	NULL
.	NULL

-	NULL
TRANSFECTED	NULL
PLASMID	NULL
:	NULL
-	NULL
HIV-1	NULL
APuB	NULL
A	NULL
NFp	NULL
AxB	NULL
10	NULL
CONVERSION	NULL
(	NULL
%	NULL
)	NULL
STIMULANT	NULL
PMA	NULL
:	NULL
-	NULL
0+	NULL
-o	NULL
k	NULL
-	NULL
@	NULL
-	NULL
0+	NULL
FOLD	NULL
INDUCTION	NULL
:	NULL
1.0	NULL
0.9	NULL
0.8	NULL
0.8	NULL
NOTES	NULL
B.	NULL
TRANSFECTED	NULL
PLASMID	NULL
:	NULL
-	NULL
HIV-1	NULL
-	NULL
APuB	NULL
ANFp	NULL
__	NULL
ArB	NULL
--	NULL
-	NULL
-CA	NULL
100	NULL
CONVERSION	NULL
(	NULL
%	NULL
)	NULL
STMULANT	NULL
PMA	NULL
:	NULL
-	NULL
4	NULL
&	NULL
0	NULL
0	NULL
-	NULL
4	NULL
&	NULL
0	NULL
-	NULL
400	NULL
-	NULL
+	NULL
FOLD	NULL
:	NULL
INDUCTION	NULL
:	NULL
7.0	NULL
9.9	NULL
5.5	NULL
1.1	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Effect	NULL
of	NULL
site-specific	NULL
HIV-1	NULL
enhancer	NULL
mutations	NULL
on	NULL
expression	NULL
in	NULL
(	NULL
A	NULL
)	NULL
the	NULL
THP-1	NULL
macrophage	NULL
leukemia	NULL
line	NULL
and	NULL
(	NULL
B	NULL
)	NULL
the	NULL
clone	NULL
13	NULL
Epstein-Barr	NULL
virus-transformed	NULL
B-cell	NULL
line	NULL
.	NULL

The	NULL
mature	NULL
monocyte	NULL
line	NULL
THP-1	NULL
was	NULL
transfected	NULL
with	NULL
the	NULL
indicated	NULL
plasmid	NULL
as	NULL
described	NULL
by	NULL
Griffin	NULL
et	NULL
al	NULL
.	NULL

(	NULL
11	NULL
)	NULL
.	NULL

Clone	NULL
13	NULL
,	NULL
an	NULL
Epstein-Barr	NULL
virus-transformed	NULL
B-cell	NULL
line	NULL
(	NULL
14	NULL
)	NULL
,	NULL
was	NULL
transfected	NULL
with	NULL
HIV-1-CAT	NULL
or	NULL
mutant	NULL
plasmids	NULL
as	NULL
described	NULL
above	NULL
.	NULL

CAT	NULL
assay	NULL
results	NULL
represent	NULL
the	NULL
average	NULL
of	NULL
two	NULL
independent	NULL
transfections	NULL
.	NULL

mutant	NULL
plasmid	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
no	NULL
increase	NULL
in	NULL
CAT	NULL
activity	NULL
was	NULL
detected	NULL
in	NULL
unstimulated	NULL
or	NULL
mitogen-activated	NULL
Jurkat	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
C	NULL
,	NULL
and	NULL
D	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
neither	NULL
site	NULL
functioned	NULL
as	NULL
a	NULL
negative	NULL
regulatory	NULL
element	NULL
.	NULL

Because	NULL
functional	NULL
activation	NULL
of	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
in	NULL
Jurkat	NULL
cells	NULL
by	NULL
PMA	NULL
,	NULL
PHA	NULL
,	NULL
or	NULL
immobilized	NULL
antibodies	NULL
to	NULL
the	NULL
T-cell	NULL
receptor	NULL
was	NULL
mediated	NULL
by	NULL
the	NULL
two	NULL
«	NULL
B	NULL
sites	NULL
in	NULL
each	NULL
case	NULL
,	NULL
we	NULL
examined	NULL
whether	NULL
these	NULL
stimulants	NULL
induced	NULL
NF-kB	NULL
binding	NULL
activity	NULL
in	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
.	NULL

Both	NULL
PMA	NULL
and	NULL
PHA	NULL
induced	NULL
binding	NULL
activity	NULL
which	NULL
was	NULL
demonstrated	NULL
in	NULL
competition	NULL
experiments	NULL
to	NULL
be	NULL
specific	NULL
for	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

As	NULL
reported	NULL
previously	NULL
(	NULL
26	NULL
)	NULL
,	NULL
cyclosporin	NULL
A	NULL
reduced	NULL
induction	NULL
of	NULL
the	NULL
kB	NULL
complex	NULL
by	NULL
PHA	NULL
but	NULL
not	NULL
PMA	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
.	NULL

This	NULL
effect	NULL
was	NULL
specific	NULL
,	NULL
because	NULL
cyclosporin	NULL
A	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
binding	NULL
to	NULL
an	NULL
unrelated	NULL
octamer	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

Although	NULL
a	NULL
nonspecific	NULL
band	NULL
was	NULL
noted	NULL
with	NULL
cross-linking	NULL
,	NULL
no	NULL
increase	NULL
in	NULL
NF-kB	NULL
binding	NULL
was	NULL
detected	NULL
when	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
cross-linked	NULL
anti-CD3	NULL
for	NULL
2	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
or	NULL
for	NULL
0.5	NULL
,	NULL
1	NULL
,	NULL
4	NULL
,	NULL
24	NULL
,	NULL
48	NULL
,	NULL
or	NULL
72	NULL
h	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
TRANSFECTED	NULL
PLASMID	NULL
:	NULL
_	NULL
HIV-1	NULL
_	NULL
APuB_	NULL
A	NULL
NFp	NULL
HTLV-I	NULL
Tez	NULL
10	NULL
[	NULL
1	NULL
CONVERSION	NULL
(	NULL
%	NULL
)	NULL
STIMULANT	NULL
tax	NULL
:	NULL
-	NULL
+	NULL
-	NULL
=+	NULL
-	NULL
0	NULL
+	NULL
-	NULL
0+	NULL
FOLD	NULL
INDUCTION	NULL
:	NULL
3.2	NULL
3.3	NULL
3.0	NULL
43.4	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

HTLV-I	NULL
fax	NULL
stimulation	NULL
of	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
and	NULL
potential	NULL
NFAT-1	NULL
site-specific	NULL
mutants	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
HIV-1	NULL
or	NULL
the	NULL
indicated	NULL
mutant	NULL
enhancer	NULL
plasmids	NULL
and	NULL
1	NULL
pug	NULL
of	NULL
a	NULL
plasmid	NULL
expressing	NULL
fax	NULL
,	NULL
(	NULL
+	NULL
)	NULL
or	NULL
an	NULL
inactive	NULL
fax	NULL
;	NULL
frameshift	NULL
mutant	NULL
(	NULL
-	NULL
)	NULL
(	NULL
17	NULL
)	NULL
.	NULL

CAT	NULL
assay	NULL
results	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
transfections	NULL
.	NULL

inability	NULL
to	NULL
detect	NULL
an	NULL
increase	NULL
in	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
with	NULL
this	NULL
method	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
very	NULL
weak	NULL
induction	NULL
of	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
seen	NULL
with	NULL
treatment	NULL
by	NULL
anti-CD3	NULL
.	NULL

We	NULL
have	NULL
examined	NULL
a	NULL
region	NULL
of	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
postulated	NULL
to	NULL
mediate	NULL
induction	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
through	NULL
binding	NULL
of	NULL
an	NULL
NFAT-like	NULL
factor	NULL
(	NULL
18	NULL
,	NULL
19	NULL
,	NULL
27	NULL
)	NULL
.	NULL

This	NULL
consideration	NULL
was	NULL
based	NULL
primarily	NULL
on	NULL
sequence	NULL
homology	NULL
and	NULL
binding	NULL
of	NULL
partially	NULL
purified	NULL
protein	NULL
to	NULL
DNA	NULL
.	NULL

The	NULL
regions	NULL
of	NULL
IL-2	NULL
homology	NULL
and	NULL
sites	NULL
protected	NULL
by	NULL
partially	NULL
purified	NULL
NFAT-1	NULL
differ	NULL
.	NULL

Because	NULL
these	NULL
sites	NULL
,	NULL
NFp	NULL
and	NULL
NF	NULL
'	NULL
p	NULL
,	NULL
lack	NULL
homology	NULL
to	NULL
the	NULL
NFAT-1	NULL
region	NULL
of	NULL
the	NULL
IL-2	NULL
enhancer	NULL
,	NULL
this	NULL
binding	NULL
may	NULL
be	NULL
due	NULL
to	NULL
contaminants	NULL
other	NULL
than	NULL
NFAT-1	NULL
,	NULL
further	NULL
suggesting	NULL
that	NULL
NFAT	NULL
-1	NULL
is	NULL
not	NULL
involved	NULL
in	NULL
HIV-1	NULL
enhancer	NULL
function	NULL
.	NULL

Lu	NULL
et	NULL
al	NULL
.	NULL

(	NULL
18	NULL
,	NULL
19	NULL
)	NULL
have	NULL
previously	NULL
introduced	NULL
a	NULL
broad	NULL
deletion	NULL
(	NULL
between	NULL
-253	NULL
and	NULL
-213	NULL
)	NULL
into	NULL
an	NULL
HIV-1	NULL
long	NULL
terminal	NULL
repeat	NULL
{	NULL
(	NULL
LTR	NULL
)	NULL
/CAT	NULL
construct	NULL
as	NULL
well	NULL
as	NULL
an	NULL
infectious	NULL
proviral	NULL
clone	NULL
and	NULL
tested	NULL
these	NULL
mutant	NULL
plasmids	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

This	NULL
deletion	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
basal	NULL
CAT	NULL
activity	NULL
and	NULL
led	NULL
to	NULL
various	NULL
modest	NULL
effects	NULL
on	NULL
induction	NULL
following	NULL
treatment	NULL
with	NULL
Probe	NULL
Octamer	NULL
p	NULL
f	NULL
A	NULL
>	NULL
s	NULL
qP	NULL
_	NULL
gt	NULL
``	NULL
=	NULL
gar	NULL
Stimulus	NULL
gat	NULL
_	NULL
g8	NULL
Cyclosporir	NULL
Sb	NULL
,	NULL
t	NULL
o~	NULL
ate	NULL
aie	NULL
:	NULL
}	NULL
A	NULL
:	NULL
~P	NULL
,	NULL
‘	NULL
.n	NULL
wo	NULL
oue	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Effect	NULL
of	NULL
PMA	NULL
,	NULL
PHA	NULL
,	NULL
and	NULL
anti-CD3	NULL
,	NULL
with	NULL
and	NULL
without	NULL
cyclosporin	NULL
A	NULL
,	NULL
on	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
were	NULL
performed	NULL
with	NULL
radiolabeled	NULL
oligonucleotide	NULL
probes	NULL
containing	NULL
either	NULL
the	NULL
«	NULL
B	NULL
site	NULL
(	NULL
A	NULL
)	NULL
or	NULL
two	NULL
copies	NULL
of	NULL
the	NULL
IL-2	NULL
octamer	NULL
(	NULL
B	NULL
)	NULL
as	NULL
described	NULL
before	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
(	NULL
2	NULL
)	NULL
were	NULL
prepared	NULL
from	NULL
unstimulated	NULL
(	NULL
-	NULL
)	NULL
Jurkat	NULL
cells	NULL
or	NULL
Jurkat	NULL
cells	NULL
incubated	NULL
for	NULL
2	NULL
h	NULL
with	NULL
the	NULL
indicated	NULL
combination	NULL
of	NULL
anti-CD3	NULL
(	NULL
OKT3	NULL
;	NULL
see	NULL
Fig	NULL
.	NULL

1	NULL
legend	NULL
)	NULL
,	NULL
PMA	NULL
(	NULL
16	NULL
nM	NULL
)	NULL
,	NULL
or	NULL
PHA	NULL
(	NULL
1	NULL
pg/ml	NULL
)	NULL
with	NULL
cyclosporin	NULL
A	NULL
(	NULL
1	NULL
ug/ml	NULL
)	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
20	NULL
,	NULL
21	NULL
)	NULL
.	NULL

Arrows	NULL
denote	NULL
specific	NULL
complexes	NULL
.	NULL

3964	NULL
NOTES	NULL
PMA	NULL
and	NULL
a	NULL
ca	NULL
.	NULL

fivefold	NULL
increase	NULL
in	NULL
viral	NULL
replication	NULL
.	NULL

Although	NULL
these	NULL
authors	NULL
suggested	NULL
that	NULL
these	NULL
effects	NULL
could	NULL
be	NULL
mediated	NULL
by	NULL
NFAT-1	NULL
,	NULL
this	NULL
deletion	NULL
eliminated	NULL
other	NULL
potential	NULL
binding	NULL
sites	NULL
and	NULL
disrupted	NULL
the	NULL
spatial	NULL
organization	NULL
of	NULL
the	NULL
LTR	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
because	NULL
T-cell	NULL
activation	NULL
generally	NULL
increases	NULL
NFAT-1	NULL
binding	NULL
activity	NULL
and	NULL
also	NULL
stimulates	NULL
HIV-1	NULL
replication	NULL
,	NULL
the	NULL
data	NULL
from	NULL
these	NULL
mutant	NULL
viruses	NULL
would	NULL
ascribe	NULL
a	NULL
previously	NULL
undetected	NULL
activity	NULL
to	NULL
NFAT-1	NULL
.	NULL

Using	NULL
site-specific	NULL
mutagenesis	NULL
,	NULL
we	NULL
now	NULL
show	NULL
that	NULL
neither	NULL
the	NULL
region	NULL
of	NULL
IL-2	NULL
homology	NULL
in	NULL
the	NULL
HIV-1	NULL
LTR	NULL
nor	NULL
the	NULL
region	NULL
which	NULL
binds	NULL
NFAT-1	NULL
mediates	NULL
stimulation	NULL
through	NULL
the	NULL
T-cell	NULL
antigen	NULL
receptor	NULL
and	NULL
that	NULL
mutation	NULL
of	NULL
these	NULL
sites	NULL
does	NULL
not	NULL
significantly	NULL
affect	NULL
basal	NULL
or	NULL
induced	NULL
levels	NULL
of	NULL
HIV-1	NULL
expression	NULL
in	NULL
several	NULL
cell	NULL
types	NULL
.	NULL

These	NULL
observations	NULL
are	NULL
consistent	NULL
with	NULL
our	NULL
previous	NULL
data	NULL
(	NULL
20	NULL
,	NULL
21	NULL
)	NULL
and	NULL
with	NULL
data	NULL
from	NULL
linker-scanning	NULL
mutants	NULL
(	NULL
34	NULL
)	NULL
,	NULL
chimeric	NULL
promoter-enhancer	NULL
constructs	NULL
(	NULL
30	NULL
)	NULL
,	NULL
and	NULL
deletion	NULL
mutants	NULL
(	NULL
28	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
it	NULL
appears	NULL
unlikely	NULL
that	NULL
NFAT-1	NULL
plays	NULL
a	NULL
direct	NULL
role	NULL
in	NULL
induction	NULL
of	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
or	NULL
that	NULL
the	NULL
purine-rich	NULL
region	NULL
of	NULL
IL-2	NULL
homology	NULL
regulates	NULL
HIV-1	NULL
expression	NULL
in	NULL
monocytes	NULL
or	NULL
lymphocytes	NULL
.	NULL

Although	NULL
it	NULL
remains	NULL
possible	NULL
that	NULL
stimulation	NULL
of	NULL
the	NULL
T-cell	NULL
antigen	NULL
receptor	NULL
may	NULL
indirectly	NULL
activate	NULL
T-cell	NULL
gene	NULL
products	NULL
,	NULL
for	NULL
example	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
,	NULL
which	NULL
activate	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
through	NULL
NF-kB	NULL
,	NULL
these	NULL
data	NULL
suggest	NULL
that	NULL
CD3-mediated	NULL
activation	NULL
plays	NULL
no	NULL
direct	NULL
role	NULL
in	NULL
activating	NULL
HIV-1	NULL
gene	NULL
expression	NULL
through	NULL
a	NULL
site	NULL
recognized	NULL
by	NULL
the	NULL
NFAT-1	NULL
transcription	NULL
factor	NULL
.	NULL

We	NULL
thank	NULL
Gerald	NULL
Crabtree	NULL
and	NULL
Cynthia	NULL
Edwards	NULL
for	NULL
helpful	NULL
discussions	NULL
and	NULL
Mara	NULL
Van	NULL
Dusen	NULL
for	NULL
typing	NULL
the	NULL
manuscript	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
Public	NULL
Health	NULL
Service	NULL
grants	NULL
CA01479	NULL
and	NULL
A130924	NULL
(	NULL
D.M.M	NULL
.	NULL
)	NULL

and	NULL
A129179	NULL
(	NULL
G.J.N	NULL
.	NULL
)	NULL

,	NULL
the	NULL
Life	NULL
and	NULL
Health	NULL
Insurance	NULL
Medical	NULL
Research	NULL
Fund	NULL
(	NULL
D.M.M	NULL
.	NULL
)	NULL

,	NULL
the	NULL
Cellular	NULL
and	NULL
Molecular	NULL
Biology	NULL
Program	NULL
(	NULL
M.C.H	NULL
.	NULL

and	NULL
G.J.N	NULL
.	NULL
)	NULL

,	NULL
and	NULL
Medical	NULL
Scientist	NULL
Training	NULL
Program	NULL
grant	NULL
NIGMS	NULL
T32	NULL
027608	NULL
(	NULL
M.C.H	NULL
.	NULL
)	NULL

.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Crabtree	NULL
,	NULL
G.	NULL
Personal	NULL
communication	NULL
.	NULL

2	NULL
.	NULL

Dignam	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
R.	NULL
M.	NULL
Lebowitz	NULL
,	NULL
and	NULL
R.	NULL
G.	NULL
Roeder	NULL
.	NULL

1983	NULL
.	NULL

Accurate	NULL
transcription	NULL
initiation	NULL
by	NULL
RNA	NULL
polymerase	NULL
II	NULL
in	NULL
a	NULL
soluble	NULL
extract	NULL
from	NULL
isolated	NULL
mammalian	NULL
nuclei	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

11:1475-1489	NULL
.	NULL

3	NULL
.	NULL

Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
J.-P.	NULL
Shaw	NULL
,	NULL
M.	NULL
R.	NULL
Bush	NULL
,	NULL
R.	NULL
E.	NULL
Replogle	NULL
,	NULL
R.	NULL
Belagaje	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1988	NULL
.	NULL

Characterization	NULL
of	NULL
antigen	NULL
receptor	NULL
response	NULL
elements	NULL
within	NULL
the	NULL
interleukin-2	NULL
enhancer	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8:1715-1724.	NULL
.	NULL

Edwards	NULL
,	NULL
C.	NULL
Personal	NULL
communication	NULL
.	NULL

.	NULL

Fauci	NULL
,	NULL
A	NULL
.	NULL

$	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
:	NULL
infectiv-ity	NULL
and	NULL
mechanisms	NULL
of	NULL
pathogenesis	NULL
.	NULL

Science	NULL
239:617-622	NULL
.	NULL

6	NULL
.	NULL

Fujita	NULL
,	NULL
T.	NULL
,	NULL
H.	NULL
Shibuya	NULL
,	NULL
T.	NULL
Ohashi	NULL
,	NULL
K.	NULL
Yamanishi	NULL
,	NULL
and	NULL
T.	NULL
Taniguchi	NULL
.	NULL

1986	NULL
.	NULL

Regulation	NULL
of	NULL
human	NULL
interleukin-2	NULL
gene	NULL
:	NULL
functional	NULL
DNA	NULL
sequences	NULL
in	NULL
the	NULL
5°	NULL
flanking	NULL
region	NULL
for	NULL
the	NULL
gene	NULL
expression	NULL
in	NULL
activated	NULL
T	NULL
lymphocytes	NULL
.	NULL

Cell	NULL
46:401-407	NULL
.	NULL

7	NULL
.	NULL

Gartner	NULL
,	NULL
S.	NULL
,	NULL
P.	NULL
Markovits	NULL
,	NULL
D.	NULL
M.	NULL
Markovitz	NULL
,	NULL
M.	NULL
H.	NULL
Kaplan	NULL
,	NULL
R.	NULL
C.	NULL
Gallo	NULL
,	NULL
and	NULL
M.	NULL
Popovic	NULL
.	NULL

1986	NULL
.	NULL

The	NULL
role	NULL
of	NULL
monocyte/	NULL
macrophages	NULL
in	NULL
HTLV-HHI/LAV	NULL
infection	NULL
.	NULL

Science	NULL
233:215-219	NULL
.	NULL

8	NULL
.	NULL

Gartner	NULL
,	NULL
S.	NULL
,	NULL
P.	NULL
Markovits	NULL
,	NULL
D.	NULL
M.	NULL
Markovitz	NULL
,	NULL
R.	NULL
F.	NULL
Betts	NULL
,	NULL
and	NULL
M.	NULL
Popovic	NULL
.	NULL

1986	NULL
.	NULL

Virus	NULL
isolation	NULL
from	NULL
and	NULL
identification	NULL
of	NULL
HTLV-III/LAV-producing	NULL
cells	NULL
in	NULL
brain	NULL
tissue	NULL
from	NULL
an	NULL
AIDS	NULL
patient	NULL
.	NULL

JAMA	NULL
256:2365-2371	NULL
.	NULL

9	NULL
.	NULL

Gorman	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
L.	NULL
F.	NULL
Moffat	NULL
,	NULL
and	NULL
B.	NULL
H.	NULL
Howard	NULL
.	NULL

1982	NULL
.	NULL

Recombinant	NULL
genomes	NULL
which	NULL
express	NULL
chloramphenicol	NULL
acetyl-transferase	NULL
in	NULL
mammalian	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

2:1044-1051	NULL
.	NULL

10	NULL
.	NULL

Greene	NULL
,	NULL
W.	NULL
C.	NULL
1990	NULL
.	NULL

Regulation	NULL
of	NULL
HIV-1	NULL
gene	NULL
expression	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

8:453-475	NULL
.	NULL

11	NULL
.	NULL

Griffin	NULL
,	NULL
G.	NULL
E.	NULL
,	NULL
K.	NULL
Leung	NULL
,	NULL
T.	NULL
M.	NULL
Folks	NULL
,	NULL
S.	NULL
Kunkel	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1989	NULL
.	NULL

Activation	NULL
of	NULL
HIV	NULL
gene	NULL
expression	NULL
during	NULL
mono	NULL
Un	NULL
4a	NULL
12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

J.	NULL
Viror	NULL
.	NULL

cyte	NULL
differentiation	NULL
by	NULL
induction	NULL
of	NULL
NF-kB	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
339:70-73	NULL
.	NULL

Hannibal	NULL
,	NULL
M.	NULL
,	NULL
L.	NULL
Zhang	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

Unpublished	NULL
data	NULL
.	NULL

Hazan	NULL
,	NULL
U.	NULL
,	NULL
D.	NULL
Thomas	NULL
,	NULL
J.	NULL
Alcami	NULL
,	NULL
F.	NULL
Bachelerie	NULL
,	NULL
N.	NULL
Israel	NULL
,	NULL
H.	NULL
Yssel	NULL
,	NULL
J.-L.	NULL
Virelizier	NULL
,	NULL
and	NULL
F.	NULL
Arenzana-Seisdedos	NULL
.	NULL

1990	NULL
.	NULL

Stimulation	NULL
of	NULL
a	NULL
human	NULL
T-cell	NULL
clone	NULL
with	NULL
anti-CD3	NULL
or	NULL
tumor	NULL
necrosis	NULL
factor	NULL
induces	NULL
NF-	NULL
«	NULL
B	NULL
translocation	NULL
but	NULL
not	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
1	NULL
enhancer-dependent	NULL
transcription	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87:7861-7865	NULL
.	NULL

Ho	NULL
,	NULL
I.-C.	NULL
,	NULL
N.	NULL
K.	NULL
Bhat	NULL
,	NULL
L.	NULL
R.	NULL
Gottschalk	NULL
,	NULL
T.	NULL
Lindsten	NULL
,	NULL
C.	NULL
B.	NULL
Thompson	NULL
,	NULL
T.	NULL
S.	NULL
Papas	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Leiden	NULL
.	NULL

1990	NULL
.	NULL

Sequence-specific	NULL
binding	NULL
of	NULL
human	NULL
Ets-1	NULL
to	NULL
the	NULL
T	NULL
cell	NULL
receptor	NULL
alpha	NULL
gene	NULL
enhancer	NULL
.	NULL

Science	NULL
250:814-818	NULL
.	NULL

Klemsz	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
S.	NULL
R.	NULL
McKercher	NULL
,	NULL
A.	NULL
Celada	NULL
,	NULL
C.	NULL
Van	NULL
Beveren	NULL
,	NULL
and	NULL
R.	NULL
A.	NULL
Maki	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
macrophage	NULL
and	NULL
B	NULL
cell-specific	NULL
transcription	NULL
factor	NULL
PU.1	NULL
is	NULL
related	NULL
to	NULL
the	NULL
ets	NULL
oncogene	NULL
.	NULL

Cell	NULL
61:113-124	NULL
.	NULL

Koenig	NULL
,	NULL
S.	NULL
,	NULL
H.	NULL
E.	NULL
Gendelman	NULL
,	NULL
J.	NULL
M.	NULL
Orenstein	NULL
,	NULL
M.	NULL
C.	NULL
Dal	NULL
Canto	NULL
,	NULL
G.	NULL
H.	NULL
Pezeshkpour	NULL
,	NULL
M.	NULL
Yungbluth	NULL
,	NULL
F.	NULL
Janotta	NULL
,	NULL
A.	NULL
Aksamit	NULL
,	NULL
M.	NULL
A.	NULL
Martin	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1986	NULL
.	NULL

Detection	NULL
of	NULL
AIDS	NULL
virus	NULL
in	NULL
macrophages	NULL
in	NULL
brain	NULL
tissue	NULL
from	NULL
AIDS	NULL
patients	NULL
with	NULL
encepha-lopathy	NULL
.	NULL

Science	NULL
233:1089-1093.	NULL
.	NULL

Leung	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1988	NULL
.	NULL

HTLV-1	NULL
transactivator	NULL
induces	NULL
interleukin-2	NULL
receptor	NULL
expression	NULL
through	NULL
an	NULL
NF-	NULL
«	NULL
B-like	NULL
factor	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
333:776-778	NULL
.	NULL

Lu	NULL
,	NULL
Y.	NULL
,	NULL
N.	NULL
Touzjian	NULL
,	NULL
M.	NULL
Stenzel	NULL
,	NULL
T.	NULL
Dorfman	NULL
,	NULL
J.	NULL
G.	NULL
Sodroski	NULL
,	NULL
and	NULL
W.	NULL
A.	NULL
Haseltine	NULL
.	NULL

1990	NULL
.	NULL

Identification	NULL
of	NULL
cis-acting	NULL
repressive	NULL
sequences	NULL
within	NULL
the	NULL
negative	NULL
regulatory	NULL
element	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:5226-5229	NULL
.	NULL

Lu	NULL
,	NULL
Y.	NULL
,	NULL
N.	NULL
Touzjian	NULL
,	NULL
M.	NULL
Stenzel	NULL
,	NULL
T.	NULL
Dorfman	NULL
,	NULL
J.	NULL
G.	NULL
Sodroski	NULL
,	NULL
and	NULL
W.	NULL
A.	NULL
Haseltine	NULL
.	NULL

1991	NULL
.	NULL

NFKB	NULL
independent	NULL
cis-acting	NULL
sequences	NULL
in	NULL
HIV-1	NULL
LTR	NULL
responsive	NULL
to	NULL
T-cell	NULL
activation	NULL
.	NULL

J	NULL
.	NULL

Acquired	NULL
Immune	NULL
Defic	NULL
.	NULL

Syndr	NULL
.	NULL

4:173-177	NULL
.	NULL

Markovitz	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
M.	NULL
Hannibal	NULL
,	NULL
V.	NULL
L.	NULL
Perez	NULL
,	NULL
C.	NULL
Gauntt	NULL
,	NULL
T.	NULL
M.	NULL
Folks	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1990	NULL
.	NULL

Differential	NULL
regulation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
viruses	NULL
(	NULL
HIV	NULL
's	NULL
)	NULL
:	NULL
a	NULL
specific	NULL
regulatory	NULL
element	NULL
in	NULL
HIV-2	NULL
responds	NULL
to	NULL
stimulation	NULL
of	NULL
the	NULL
T-cell	NULL
antigen	NULL
receptor	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87:9098-9102	NULL
.	NULL

Nabel	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1987	NULL
.	NULL

An	NULL
inducible	NULL
transcription	NULL
factor	NULL
activates	NULL
expression	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
326:711-713	NULL
.	NULL

Osborn	NULL
,	NULL
L.	NULL
,	NULL
S.	NULL
Kunkel	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1989	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
a	NULL
and	NULL
interleukin	NULL
1	NULL
stimulate	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
enhancer	NULL
by	NULL
activation	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
kB	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86:2336-2340	NULL
.	NULL

Petterson	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
W.	NULL
Schaffner	NULL
.	NULL

1987	NULL
.	NULL

A	NULL
purine-rich	NULL
DNA	NULL
sequence	NULL
motif	NULL
present	NULL
in	NULL
SV40	NULL
and	NULL
lymphotropic	NULL
papovavirus	NULL
binds	NULL
a	NULL
lymphoid-specific	NULL
factor	NULL
and	NULL
contributes	NULL
to	NULL
enhancer	NULL
activity	NULL
in	NULL
lymphoid	NULL
cells	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

1:962-972	NULL
.	NULL

Queen	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1983	NULL
.	NULL

Immunoglobulin	NULL
gene	NULL
transcription	NULL
is	NULL
activated	NULL
by	NULL
downstream	NULL
sequence	NULL
elements	NULL
.	NULL

Cell	NULL
33:741-748	NULL
.	NULL

Rosen	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
J.	NULL
G.	NULL
Sodroski	NULL
,	NULL
and	NULL
W.	NULL
A.	NULL
Haseltine	NULL
.	NULL

1985	NULL
.	NULL

The	NULL
location	NULL
of	NULL
cis-acting	NULL
regulatory	NULL
sequences	NULL
in	NULL
the	NULL
human	NULL
T	NULL
cell	NULL
lymphotrophic	NULL
virus	NULL
type	NULL
III	NULL
(	NULL
HTLV-III/LAV	NULL
)	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

Cell	NULL
41:813-823	NULL
.	NULL

Schmidt	NULL
,	NULL
A.	NULL
,	NULL
L.	NULL
Henninghausen	NULL
,	NULL
and	NULL
U.	NULL
Siebenlist	NULL
.	NULL

1990	NULL
.	NULL

Inducible	NULL
nuclear	NULL
factor	NULL
binding	NULL
to	NULL
the	NULL
kB	NULL
elements	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
enhancer	NULL
in	NULL
T	NULL
cells	NULL
can	NULL
be	NULL
blocked	NULL
by	NULL
cyclosporin	NULL
A	NULL
in	NULL
a	NULL
signal-dependent	NULL
manner	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:4037-4041	NULL
.	NULL

Shaw	NULL
,	NULL
J.-P.	NULL
,	NULL
P.	NULL
J.	NULL
Utz	NULL
,	NULL
D.	NULL
B.	NULL
Durand	NULL
,	NULL
J.	NULL
J.	NULL
Toole	NULL
,	NULL
E.	NULL
A.	NULL
Emmel	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1988	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
putative	NULL
regulator	NULL
of	NULL
early	NULL
T	NULL
cell	NULL
activation	NULL
genes	NULL
.	NULL

Science	NULL
241:202-205	NULL
.	NULL

Siekevitz	NULL
,	NULL
M.	NULL
,	NULL
S.	NULL
F.	NULL
Josephs	NULL
,	NULL
M.	NULL
Dukovich	NULL
,	NULL
N.	NULL
Peffer	NULL
,	NULL
F.	NULL
Wong-Staal	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Greene	NULL
.	NULL

1987	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
by	NULL
T	NULL
cell	NULL
mitogens	NULL
and	NULL
the	NULL
transactivator	NULL
protein	NULL
of	NULL
HTLV-I	NULL
.	NULL

Science	NULL
238:1575-1578	NULL
.	NULL

Thompson	NULL
,	NULL
C.	NULL
B.	NULL
,	NULL
C.	NULL
Y.	NULL
Wang	NULL
,	NULL
I.	NULL
C.	NULL
Ho	NULL
,	NULL
P.	NULL
R.	NULL
Bohjanen	NULL
,	NULL
B.	NULL
Petryniak	NULL
,	NULL
C.	NULL
H.	NULL
June	NULL
,	NULL
S.	NULL
Miesfeldt	NULL
,	NULL
L.	NULL
Zhang	NULL
,	NULL
G.	NULL
J.	NULL
Nabel	NULL
,	NULL
B.	NULL
Karpinski	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Leiden	NULL
.	NULL

1992.	NULL
cis-Acting	NULL
sequences	NULL
required	NULL
for	NULL
inducible	NULL
interleukin-2	NULL
enhancer	NULL
function	NULL
bind	NULL
a	NULL
novel	NULL
Ets-related	NULL
protein	NULL
,	NULL
Elf-1	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12:1043-1053	NULL
.	NULL

Vor	NULL
.	NULL

66	NULL
,	NULL
1992	NULL
30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

Tong-Starksen	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
P.	NULL
A.	NULL
Luciw	NULL
,	NULL
and	NULL
B.	NULL
M.	NULL
Peterlin	NULL
.	NULL

1987	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
long	NULL
terminal	NULL
repeat	NULL
responds	NULL
to	NULL
T-cell	NULL
activation	NULL
signals	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
84	NULL
:	NULL
6845-6849	NULL
.	NULL

Tong-Starksen	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
P.	NULL
A.	NULL
Luciw	NULL
,	NULL
and	NULL
B.	NULL
M.	NULL
Peterlin	NULL
.	NULL

1989	NULL
.	NULL

Signaling	NULL
through	NULL
T	NULL
lymphocyte	NULL
surface	NULL
proteins	NULL
,	NULL
TCR/CD3	NULL
and	NULL
CD28	NULL
,	NULL
activates	NULL
the	NULL
HIV-1	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

142:702-707	NULL
.	NULL

Tong-Starksen	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
T.	NULL
M.	NULL
Welsh	NULL
,	NULL
and	NULL
B.	NULL
M.	NULL
Peterlin	NULL
.	NULL

1990	NULL
.	NULL

Differences	NULL
in	NULL
transcriptional	NULL
enhancers	NULL
of	NULL
HIV-1	NULL
and	NULL
HIV-2	NULL
:	NULL
33	NULL
.	NULL

34	NULL
.	NULL

NOTES	NULL
3965	NULL
response	NULL
to	NULL
T	NULL
cell	NULL
activation	NULL
signals	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

145:4348-4354	NULL
.	NULL

Wang	NULL
,	NULL
C.-Y	NULL
.	NULL

,	NULL
B.	NULL
Petryniak	NULL
,	NULL
I.-C.	NULL
Ho	NULL
,	NULL
C.	NULL
B.	NULL
Thompson	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Leiden	NULL
.	NULL

Evolutionarily	NULL
conserved	NULL
sub-families	NULL
of	NULL
ets	NULL
proteins	NULL
display	NULL
distinct	NULL
DNA	NULL
binding	NULL
specificities	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
in	NULL
press	NULL
.	NULL

Zeichner	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
J.	NULL
Y.	NULL
H.	NULL
Kim	NULL
,	NULL
and	NULL
J.	NULL
C.	NULL
Alwine	NULL
.	NULL

1991	NULL
.	NULL

Linker-scanning	NULL
mutational	NULL
analysis	NULL
of	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

6§:2436-2444	NULL
.	NULL

